Multi-site HPV Screening by High-throughput Sequencing in Patients With Chronic HPV-HR Infection Followed by Gynecology

NCT04901351

Status	RECRUITING
Phase	Not Applicable
Sponsor	University Hospital, Toulouse
Enrollment	30 participants

Plain Language Summary

This study uses advanced genetic sequencing technology to screen for multiple types of high-risk HPV (human papillomavirus) in women who have had persistent or recurring HPV-related cervical or vaginal abnormalities. The goal is to better identify which HPV strains are present.

You may be eligible if...
- You have a persistent high-risk HPV infection lasting at least 6 months after treatment for a cervical or vaginal abnormality
- You have had a recurrence of a high-grade cervical lesion (CIN2, CIN3, or HSIL) or a recurrence of cervical or vaginal cancer
- You have given written consent to participate
- You are covered by social security in France

You may NOT be eligible if...
- Your HPV infection involves only low-risk HPV strains (not the high-risk types linked to cancer)

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (3)

- Chronic infected patients defined by: Patients with persistent HPV-HR cytological infection (high risk) (as early as 6 months post-treatment of a cervical or vaginal injury), or a recurrence of a high-grade squamous intraepithelial lesion (CIN2 or CIN3 or HSIL) or a recurrence of cancer in the cervix or vagina
- Patients who have given their written consent to participate in the study.
- Person affiliated or beneficiary of a social security scheme.

Exclusion (1)

- Patient with an infection or a persistent lesion after treatment or not, linked only to low-risk HPV.

Locations (1 total)

CHU Toulouse, Toulouse, France